ELEKTA INITIATES REPURCHASE OF OWN SHARES

ELEKTA INITIATES REPURCHASE OF OWN SHARES

PRESS RELEASE			
Stockholm, July 4, 2007

Elekta has on July 4, 2007, repurchased 154,200 B shares at an average price of
SEK 117.37. Elekta's current holding of own shares (treasury stock) amounts to
913,471 B shares. The total number of shares in Elekta as of 31 May, 2007 is
93,794,776.

The repurchases currently being carried out follows the Board's decision on July
2, 2007, to mandate executive management to initiate on appropriate occasions
the repurchase of shares amounting up to SEK 100 M, but maximized to 1,000,000
shares.

For information regarding implementation of additional purchases within this
mandate, Elekta offers reference continually to
http://omxgroup.com/nordicexchange.

Purchases will be made on the Nordic Exchange and at a price within the
registered price interval at the time of each purchase. Purchases may be made
during the period until the next Annual General Meeting. Elekta's Board intends
to suggest to the AGM that repurchased shares are cancelled.

********

For further information, please contact:

Okee Williams 
Corporate Communications, Elekta AB 
Tel: +46 70 600 53 64 (mobile), e-mail: okee.williams@elekta.com 

About Elekta

Elekta is an international medical-technology Group, providing meaningful
clinical solutions, comprehensive information systems and services for improved
cancer care and management of brain disorders. All of Elekta's solutions employ
non-invasive or minimally invasive techniques and are therefore clinically
effective, gentle on the patient and cost-effective. 

Clinical solutions include among others Leksell Gamma Knife® for non-invasive
treatment of brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April
2005, the Elekta Group is the world's largest supplier of oncology software. 

Elekta's systems and solutions are used at over 4,000 hospitals around the world
to treat cancer and manage clinical operations as well as to diagnose and treat
brain disorders, including tumors, vascular malformations and functional
disorders.  

With approx. 2,000 employees, Elekta's corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Nordic Exchange under the
ticker EKTAb. For more information about Elekta, please visit www.elekta.com.